Article

Seven MFN and IRP mistakes that can put millions at risk

  • Rafael de Alencar headshot

    Rafael de Alencar, MSc

Avoid costly pricing missteps by understanding the common MFN and IRP risks that can impact global pricing strategy, market access, and long-term revenue.
As Most Favored Nation and international reference pricing models evolve, manufacturers face growing pressure to protect global price integrity. A single visible price, discount, or access decision can influence payer expectations across markets, affecting launch sequencing, negotiations, and long-term revenue.

This article outlines seven common MFN and IRP mistakes — and the practical steps manufacturers can take to quantify exposure early, strengthen governance, defend value, and reduce cross-market spillover risk.

Click below to read the full article and learn more:

We're here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.
abstract

Related resources

Interview

AMCP Nexus 2026: Insights shaping market access strategy

Interview

5 questions about the evolving biosimilar landscape

Interview

5 questions on payer engagement with pre-approval information exchange (PIE)